Ovid to Focus on OV882, Potential RNA Therapy for Angelman

Ovid to Focus on OV882, Potential RNA Therapy for Angelman

292412

Ovid to Focus on OV882, Potential RNA Therapy for Angelman

Ovid Therapeutics is stopping its clinical program for OV101 (gaboxadol), a candidate therapy for both Angelman and fragile X syndrome, in favor of focusing its resources on OV882, a potential RNA therapy for Angelman patients, it announced in a corporate update. The decision to discontinue OV101 follows data from several clinical trials, including the Phase 3 NEPTUNE study (NCT04106557) in children with Angelman syndrome. Despite being well-tolerated with no significant safety issues, efficacy outcomes seen with OV101 “do…

You must be logged in to read/download the full post.